Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Lidocaine hydrochloride + povidone-iodine + isopropyl alcohol + methylprednisolone** is a marketed combination injection kit sold as **DYURAL L KIT** under the DYURAL product line. The therapeutically active anti-inflammatory component is **methylprednisolone acetate**, a synthetic glucocorticoid small molecule that binds the **glucocorticoid receptor** to suppress inflammatory and immune signaling; the kit also includes **lidocaine hydrochloride** as a local anesthetic and **povidone-iodine** plus **isopropyl alcohol** as topical antiseptics for skin preparation before injection. The product is used for intramuscular, intra-articular, soft tissue, and intralesional administration across a broad range of inflammatory, allergic, autoimmune, dermatologic, rheumatologic, pulmonary, hematologic, renal, neurologic, ophthalmic, and neoplastic conditions. Public labeling indicates that this is an unapproved drug product whose labeling has not been approved by the FDA and which has not been found by FDA to be safe and effective.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine hydrochloride + povidone-iodine + isopropyl alcohol + methylprednisolone.